Background: Heat shock proteins (Hsp) are known to enhance cell survival under various stress conditions. In the heart, the small Hsp20 has emerged as a key mediator of protection against apoptosis, remodeling, and ischemia/reperfusion injury. Moreover, Hsp20 has been implicated in modulation of cardiac contractility ex vivo. The objective of this study was to determine the in vivo role of Hsp20 in the heart and the mechanisms underlying its regulatory effects in calcium (Ca) cycling.
T he 17-kDa chaperone protein heat shock protein 20 (Hsp20) belongs to a family of at least 10 different small Hsp, which transiently increase to enhance cell survival in stress conditions. 1 Hsp20 is expressed in multiple tissues, but it is most abundant in muscle. 1 Of note, the levels of Hsp20 are increased in animal or human hearts under ischemic conditions, 2 exercise training, 3 rapid right ventricular pacing, 4 pharmacological treatment by doxorubicin, 5 and chronic ␤-adrenergic stimulation. 6 Currently, the functional significance of Hsp20 has been extensively studied in smooth and cardiac muscles. 1, 7 In the heart, Hsp20 protects against ischemia/reperfusion-induced injury, 8 ␤-agonist-mediated remodeling, 6 and apoptosis. 6, 9 Thus, the increased Hsp20 ex-pression in failing hearts may constitute an important compensatory mechanism. Interestingly, acute increases of Hsp20 levels or activity in isolated cardiomyocytes are also associated with enhanced contractile parameters, suggesting an additional role of Hsp20 function in the heart. 10, 11 However, the mechanisms and subcellular pathways underlying the Hsp20-mediated effects on contractility have not been identified.
Cardiac contractility and calcium (Ca) cycling are regulated by a fine equilibrium of protein phosphorylation, which is enacted by the balance of protein kinase and phosphatase activities. 12 Reversible Ser/Thr protein phosphorylation represents the cellular basis for integration of key signaling pathways and the responses of the heart to increased demands during sympathetic stimulation. 12 The majority of Ser/Thr phosphatase activity is attributed to type 1 protein phosphatase (PP1) and type 2 phosphatases. [13] [14] [15] [16] Among these phosphatases, PP1 is of particular importance because it has been implicated as an important negative regulator of cardiac function. 13, 17, 18 In fact, increases in its levels and activity have been suggested to play a major role in the aberrant sarcoplasmic reticulum (SR) Ca cycling and pathogenesis of heart failure. 12, 19 Accordingly, overexpression of the PP1 catalytic subunit in the mouse heart, at levels similar to those observed in human failing hearts, strongly suppressed contractility and induced heart failure. 18 Current evidence indicates that substrate specificity for this versatile enzyme is achieved through its auxiliary proteins, which target it to subcellular compartments. 12 In cardiac muscle, PP1 is present in the sarcoplasmic reticulum and it is the main phosphatase that dephosphorylates phospholamban (PLN), impacting SERCA2a activity and cardiac performance. 12, 14, 19 Furthermore, PP1 activity is regulated by two endogenous proteins, inhibitor-1 and inhibitor-2. 12, 20 Genetic manipulations of either inhibitor molecule have supported their important role in regulation of PP1 and the critical involvement of this enzyme in the pathogenesis of heart failure. 18,20 -23 However, it is not currently clear whether there are any additional endogenous protein partners of PP1 that may modify its activity.
Interestingly, the present study identified the small chaperone Hsp20 as a novel regulator of PP1 activity in the heart. Regulation appears to involve a direct physical interaction of Hsp20 with PP1 and inhibition of its enzymatic activity. This is associated with specific increases in PLN phosphorylation, SR Ca transport, and Ca load, leading to augmented function. The present findings, coupled with previous observations on the cardioprotective function of Hsp20 in vivo, suggest that Hsp20 may have a dual beneficial role in the heart, increasing both cell survival and SR Ca cycling.
Materials and Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org and includes detailed information regarding the generation of Hsp20 transgenic mice, in vivo catheterization, ex vivo Langendorff perfusion, mouse left ventricular myocyte isolation and measurements of mechanics, Ca kinetics and electrophysiology, quantitative immunoblotting, SR Ca uptake, adult rat and mouse ventricular myocyte isolation and adenovirus-mediated gene transfer, isolation of cardiac microsomes enriched in SR membranes, PP1 activity assay, coimmunoprecipitations, immunofluorescence studies, generation of recombinant proteins, blot overlay assay, and statistical analyses.
Results

Overexpression of Hsp20 Enhances Global Cardiac Contractile Function
Previous ex vivo studies suggested an effect of Hsp20 on cardiac contractility. 10, 11, 24 To delineate the functional effects of Hsp20 in vivo, left ventricular contractile indices of Hsp20 transgenic mice were measured using cardiac catheterization. As shown in the Table, the systolic function, determined by the maximal rate of pressure increase, was significantly higher in Hsp20 hearts, compared with wild types (WT). The arterial blood pressure and maximal pressure were not different between the two groups. Diastolic parameters were also increased in Hsp20 hearts, as evidenced by restoration of the maximal rate of decline of left ventricular systolic pressure (Table) . In addition, the minimum pressure (a surrogate of ventricular diastolic suction) and relaxation constant (Tau, a measure of active relaxation) were decreased in Hsp20 hearts. Consistently, Langendorff perfused Hsp20 transgenic (TG) hearts with a fixed pressure of 70 cm H 2 O showed increased contractile parameters compared with WT hearts (Online Figure I ). Taken together, these findings indicate that increased Hsp20 expression in the adult heart enhances cardiac performance. 
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Hsp20 Enhances Contractility and SR Ca Cycling in Cardiomyocytes
To determine the mechanisms associated with the enhanced cardiac contractility by Hsp20, we evaluated the mechanical parameters and Ca transients in isolated cardiomyocytes, which represent a load-independent system. Overexpression of Hsp20 resulted in significant increases in fractional shortening (FS%), rates of contraction (ϩdL/dt), and rates of relaxation (ϪdL/dt), compared to WT (PϽ0.05; Figure 1A through 1D). Accordingly, the peak of the Ca transient was significantly increased and the Ca decay rate (50% time constant of Ca transient decay) was abbreviated in TG myocytes relative to controls (PϽ0.01; Figure 1E through 1G). Furthermore, the caffeine-induced Ca transient peak was elevated compared with WT myocytes (PϽ0.01; Figure 1H and 1I), indicating a higher SR Ca content. However, the caffeine-induced 50% time constant of Ca transient decay, which mainly reflects the Ca extrusion by sodium/calcium exchanger (NCX), was not different between TG and WT myocytes ( Figure 1J ). Collectively, these data indicate that overexpression of Hsp20 increases cardiomyocyte Ca cycling and contractile performance.
Hsp20 Does Not Alter the Levels of Major Ca Handling Proteins
Given the central role of SR Ca cycling proteins in cardiac contractility, 25 it was important to examine whether overexpression of Hsp20 poses any effects on their expression levels. Quantitative immunoblotting analysis did not reveal any significant changes in total levels of SERCA2a, phospholamban, ryanodine receptor 2, calsequestrin, NCX, and L-type Ca channel (Figure 2A and 2B). The activities of the L-type Ca channel and NCX were further investigated using whole-cell voltage clamps. Neither Ca currents in response to a series of depolarizing steps from a holding potential of Ϫ50 mV ( Figure 2C ) nor the average Ca current-voltage relationship ( Figure 2D ) showed differences between TG and WT ventricular cells. Furthermore, the Ni 2ϩ -sensitive I NCX current ( Figure 2E ) and the I NCX density ( Figure 2F ), which were calculated by normalizing total current to cell membrane capacitance, were similar between Hsp20 TG and Hsp20 WT myocytes. Together, these data indicate that the enhanced cardiac function by Hsp20 is not associated with alterations in SR Ca handling proteins or the activities of L-type Ca channel and NCX.
Hsp20 Increases Phosphorylation of PLN and Enhances SR Ca Transport
Because there were no differences in the expression levels of SR Ca cycling proteins or the activities of L-type Ca channel and NCX, we further investigated the phosphorylation status of key Ca cycling proteins in TG and WT hearts, which constitutes an important regulatory mechanism governing cardiac contractility. 25 Interestingly, phosphorylation of PLN at Ser16 and Thr17 in TG hearts was significantly increased compared to WT ( Figure 3A and 3B; PϽ0.01). However, the phosphorylation of ryanodine receptor 2 at Ser2809 or Ser2815 was not altered ( Figure 3A and 3B ). Furthermore, there was no increase in the phosphorylation of myofibrillar proteins, troponin I, or myosin-binding protein-C ( Figure 3A and 3B). These results suggest that Hsp20 shows apparent specificity for PLN phosphorylation. Because the degree of PLN phosphorylation profoundly affects the activation state of SERCA2a and contractility, 26 we next assessed the initial rates of ATP-dependent, oxalatefacilitated SR Ca uptake in cardiac homogenates over a wide range of Ca concentrations, similar to those present in the cardiomyocyte during relaxation and contraction. The incubation conditions in cardiac homogenates, which restrict Ca uptake to SR vesicles, have been defined previously. 27 Our results revealed that Hsp20 overexpression significantly enhanced the affinity of SERCA2a for Ca (EC 50 , Figure 3C inset). Furthermore, no differences in the maximal velocity of SR Ca uptake were noted between the two groups ( Figure  3C ). These findings indicate that overexpression of Hsp20 in the heart alleviates the PLN inhibition on SERCA2a by enhancing the phosphorylation status of PLN.
Further support for the apparent specificity of Hsp20 for PLN was provided by studies in a transgenic mouse model, which expresses nonphosphorylatable PLN (S16A, T17A double-mutant in the null background 27 without any alterations in endogenous Hsp20 levels; Online Figure II ). Isolated adult cardiomyocytes from double-mutant and WT mice were infected with Ad.GFP or Ad.Hsp20 for 24 hours before assessment of their contractile parameters. As expected, overexpression of Hsp20 in WT cardiomyocytes significantly increased fractional shortening percentage, ϩdL/dt, and ϪdL/dt, which were accompanied by en- hanced Ca kinetics compared with Ad.GFP controls (Figure 4A-D) . However, there were no significant stimulatory effects of Hsp20 in double-mutant PLN cardiomyocytes ( Figure 4A through 4D) . Furthermore, infection of adult mouse cardiomyocytes from the PLN-KO model with Ad.GFP or Ad.Hsp20 showed no differences in either contractile parameters or Ca transients between these two groups (Online Figure III) . Collectively, these data further support the role of PLN phosphorylation in the inotropic effects of Hsp20 in the heart.
Overexpression of Hsp20 Regulates PP1 Activity
The phosphorylation status of PLN is largely determined by the balance between protein kinases and phosphatases, including PP1 and PP2A. To investigate whether Hsp20 may tilt this fine-tuned balance, resulting in PLN hyperphosphorylation, we determined the protein phosphatase activities in Hsp20 TG and WT hearts. Our results showed that PP1 activity was significantly decreased in Hsp20-hearts compared with WT ( Figure 5A ). However, there was no difference in PP2A activity between Hsp20 and WT hearts ( Figure  5A ). To further verify the effects of Hsp20 on PP1 activity, adult rat cardiomyocytes were infected with either Ad.Hsp20 or Ad.GFP. Consistent with our in vivo findings, acute Hsp20 overexpression was associated with decreases in PP1 activity ( Figure 5B ). Taken together, these results suggest that Hsp20 may specifically regulate PP1 activity.
Hsp20 Interacts With PP1 in Cardiomyocytes
Early studies indicated that the substrate specificity of PP1 is dictated by its subcellular localization, and this enzyme appears to be the main SR phosphatase responsible for dephosphorylating PLN. 28 To determine whether the regulatory effect of Hsp20 on PP1 is attributable to its subcellular localization in SR, microsomal preparations enriched in SR membranes and their respective cytosolic fractions were isolated from TG and WT hearts ( Figure 6A ). Both PLN and PP1 were abundantly present in the SR-enriched membrane fraction. Hsp20 was mainly present in the cytosolic fraction Immunoblots revealed that pSer16-PLN/PLN and pThr17-PLN/ PLN were significantly increased in TG compared with WT hearts, but the phosphorylation levels of Ser2809-RYR2, Ser2815-RyR2, Ser23/24-TnI, and Ser282-MyBP-C were not different between WT and TG hearts (nϭ6 for each protein). ValuesϭmeanϮSEM. *PϽ0.01. C, Initial rates of oxalatesupported SR Ca uptake in hearts from WT (OE) and Hsp20 TG (f) mice. There was no difference in the maximal SR Ca uptake rates, but the EC 50 value significantly decreased (inset) in TG hearts compared to WT hearts (nϭ5 for each group). Experiments were performed in duplicates. ValuesϭmeanϮSEM. #PϽ0.05. and overexpression increased its abundance in cytosolic and microsomal fractions of TG hearts.
Considering that Hsp20 was present in the SR membrane fraction, we hypothesized that this protein may colocalize with PLN and PP1. Therefore, its subcellular localization was assessed using coimmunostaining with PLN and PP1 antibodies in WT and TG cardiomyocytes. PLN staining revealed a striated pattern, corresponding to the SR membrane system ( Figure 6B ). Interestingly, immunofluorescence staining of Hsp20 also produced a partially striated pattern, overlapping with PLN ( Figure 6B ). Furthermore, double staining with PP1 and Hsp20 antibodies revealed colocalization of these two proteins in a similar pattern ( Figure 6C ). These results suggest that Hsp20 colocalizes with PP1 and PLN in the heart.
The potential association between Hsp20 and PP1 was further confirmed by reciprocal coimmunoprecipitations using antibodies against Hsp20 and PP1 in cardiac homogenates. PP1 was detected by Western blot analysis of anti-Hsp20 immunoprecipitates ( Figure 6D, upper panel) . Accordingly, the reverse immunoprecipitation indicated that Hsp20 was associated with PP1 ( Figure 6D , lower panel).
To determine whether the observed association between Hsp20 and PP1 is direct, and to narrow the regions on these 2 proteins responsible for their physical interaction, various recombinant PP1 and Hsp20 constructs were generated. Recombinant full-length (PP1 (aa1-330) ) and 2 deletion constructs of PP1 (PP1 (aa1-187) and PP1 (aa163-330) ) were generated in fusion with the maltose-binding protein (MBP; Figure 6E and 6G). In addition, an Hsp20 construct containing residues 1 to 160 (Hsp20 (aa1-160) ) and 2 deletion constructs (Hsp20 (aa1-82) and Hsp20 (aa73-160) ) were expressed as glutathione-Stransferase (GST)-fusion proteins in Escherichia coli ( Figure  6F and 6I) . Using blot overlay assays, we evaluated binding of GST-Hsp20 (aa1-160) (Ϸ40 kDa) to the full-length and the 2 truncated MBP-PP1 proteins. Full-length MBP-PP1 (aa1-330) and MBP-PP1 (aa163-330) showed strong binding to GST-Hsp20 (aa1-160) , therefore mapping the region of PP1 required for its association with Hsp20 to residues 163 to 330 ( Figure  6H) . Similarly, on reciprocal blot overlay experiments, we evaluated binding of MBP-PP1 (aa1-330) (Ϸ80 kDa) to the full-length GST-Hsp20 (aa1-160) and the 2 Hsp20 deletion constructs GST-Hsp20 (aa1-82) and GST-Hsp20 (aa73-160) . We found that GST-Hsp20 (aa1-160) and GST-Hsp20 (aa73-160) interacted with MBP-PP1 (aa1-330) ( Figure 6J ). Taken together, these data suggest that Hsp20 and PP1 directly interact with each other and that the region involved in their binding is within their C-terminal domains.
Discussion
This study presents the first evidence on inhibition of PP1 by the small Hsp20. PP1 is a major Ser/Thr protein phosphatase in the cardiomyocytes, where its activity is regulated by the endogenous inhibitor-1 and inhibitor-2 proteins. 12,13,18,20 -23,29 Herein we identified an additional control switch for PP1 enzymatic activity provided by the cardioprotective protein Hsp20. Regulation of PP1 by Hsp20 involves a physical direct interaction between these two proteins, leading to amplified SR Ca cycling and augmented cardiac inotropy (Figure 7) .
Previous studies have shown that inhibition of PP1 activity in genetic models through overexpression/activation of inhibitor-1 or inhibitor-2 results in a hypercontractile cardiac phenotype. 22, 29, 30 These findings are compatible with the idea that suppression of PP1 activity increases the phosphorylation status of PLN with subsequent disinhibition of SERCA2a, enhanced SR Ca uptake, and SR Ca load. The apparent specificity of Hsp20 toward PLN was further confirmed in acutely infected cardiomyocytes from: (1) PLN doublemutant mice, which abrogated the stimulatory effects of Hsp20 on contractile and Ca kinetic parameters in the absence of the Ser16 and Thr17 phosphorylation sites ( Figure  4A through 4D); and (2) PLN-KO mice, which prevented the Hsp20 stimulatory effects in the absence of PLN (Online Figure III ). Although these studies in isolated cardiomyocytes represent an ex vivo system with limited functional analysis, they offer an advantage over cross models, which may develop compensatory mechanisms contributing to the observed phenotype. This unique preference of Hsp20 for PLN may be important from a therapeutic point of view because increased ryanodine receptor phosphorylation may poten- tially lead to diastolic leakiness and arrhythmogenic activity in failing hearts. 31 It should be noted that additional modulators of SERCA activity exist, such as the membrane-associated antiapoptotic protein Bcl-2, 32 which has been shown to underlie one of the Hsp20 mechanisms, preventing cardiac ischemia/reperfusion injury. 8 However, Hsp20 did not alter the expression level of Bcl-2 and coimmunoprecipitation studies excluded a direct association between these two proteins. 8 Thus, the Hsp20 regulatory effects on cardiac contractility do not appear to be mediated by the Bcl-2/SERCA pathway. Interestingly, Hsp20 appeared to coimmunoprecipitate not only with PP1, as Figure 6 . Interaction of heat shock protein 20 (Hsp20) with type 1 protein phosphatase (PP1). A, Representative blots of Hsp20, phospholamban (PLN), PP1, GAPDH, and ␣-actinin in microsomes enriched in sarcoplasmic reticulum (SR) membranes or in cytosolic fractions from wild-type (WT) and Hsp20 transgenic (TG) hearts (nϭ6). The yield of cardiac SR and cytosolic proteins averaged 1.5 mg per heart and 12 mg per heart, respectively. The amount of total protein on each gel lane was the same (20 g for each fraction), which diluted the cytosolic fraction by 10-times compared to the SR fraction. B, WT and TG cardiomyocytes were immunostained for Hsp20 (red) in combination with PLN (green). C, WT and TG cardiomyocytes were immunostained for Hsp20 (green) in combination with PP1 (red). Scale bar, 10 m. D, Coimmunoprecipitation was performed using anti-Hsp20 or anti-PP1 antibody and cardiac homogenates (200 g total protein) of WT and Hsp20 TG mice. The precipitates were analyzed by immunoblotting with anti-Hsp20 or anti-PP1 antibodies, as indicated. Pre-immunoprecipitated WT heart homogenate was used as positive control (ϩ), and immunoprecipitate with anti-IgG PLUS agarose was used as negative control (Ϫ). IP indicates immunoprecipitation. E, Diagrammatic representation of the full-length and the two deletion constructs of PP1 and (F) the full-length and the two deletion constructs of Hsp20. Predicted protein domains are shown in gray. G, SDS gel stained with Coomassie blue showing the purified maltose-binding protein (MBP)-PP1 full-length or deletion proteins. H, Blot overlay assays with anti-GST antibody (WB65306GST-Ab) were performed to determine the protein region of PP1 required for its association with GST-Hsp20 (aa1-160) . This narrowed the PP1 binding region to a C-terminal fragment including amino acids 163 to 330. I, SDS gel stained with Coomassie blue showing the purified GST-Hsp20 full-length or deletion proteins. J, Blot overlay assays with anti-MBP antibody (Western blot: MBP-Ab) determined that the protein region of Hsp20 responsible for its binding with MBP-PP1 (aa1-330) includes amino acids 73 to 160. WB indicates Western blot.
indicated, but also with inhibitor-1 (Online Figure IV) , suggesting the presence of a multiprotein regulatory complex. However, it is not currently known whether Hsp20 associates with inhibitor-1 directly or indirectly via PP1.
The mechanisms underlying the apparent specificity of Hsp20 for hyperphosphorylation of PLN may involve the location of PP1 within the proper SERCA/PLN functional domain of the SR. It has been recognized that PP1 associates with specific subunits or regulatory proteins, which target it to different subcellular locations/compartments, modulating its activity toward unique substrates. 12 In the heart, it is suggested that PP1 associates with SR through its glycogenbinding subunit, which contains a hydrophobic SR anchoring region. 33 This would allow for PP1 compartmentalization and amplification of the Hsp20 effects on phospholamban phosphorylation through the PP1/PLN axis. Interestingly, Hsp20 is also present in the SR-enriched fraction and there appears to be an association between PP1 and Hsp20. Recombinant protein assays confirmed a physical interaction between Hsp20 and PP1. Thus, Hsp20, PP1, and PLN may comprise a supramolecular complex, facilitating the targeting of PP1 toward the SR-associated PLN.
Recently, two distinct peptide motifs, which are responsible for the interaction of regulatory proteins with PP1, have been documented: (1) [R/K]-x(0,1)-V-x-F, a well-characterized and conventional consensus motif, which binds to the C-terminal region of PP1 catalytic subunit; and (2) F-x-x-[R/K]-x-[R/K], which was initially identified in Bcl-x L , Bcl-w, and Bad proteins, but its binding site on PP1 catalytic subunit is still unknown. 34, 35 By sequence screening, we found that Hsp20 does not contain the [R/K]-x(0,1)-V-x-F motif. However, the region between residues 117 and 122 (FHRRYR), which locates within a predicted C-terminal protein-protein interaction domain, possesses criteria for a putative F-x-x-[R/K]-x-[R/K] motif binding to PP1 (Online Figure V) . Our GST pull-down assay confirmed that the C-terminal region of Hsp20 (aa73-160) binds to PP1 catalytic subunit ( Figure 6I and 6J).
A previous study showed that incubation of transiently permeabilized myocytes with phospho-Hsp20 peptide analogues, which contain the N-terminal 13 amino acids of Hsp20, increased contractility associated with an abbreviated Ca transient decay. 11 However, the nonphosphorylated peptide with similar length had no effects on contractility. 11 The apparent discrepancy between the effects of nonphosphorylated peptide analogues and our results may be attributable to differences in peptide length, techniques used, experimental conditions, and models. Consistent with our current findings, another chaperone protein, Hsp70, has been identified as an SR Ca regulatory protein. 36 Deletion of Hsp70 resulted in a delayed decline of Ca transients, decreased SR Ca content, and decreased rates of contraction and relaxation, which were related to decreases in SERCA2a expression. 36 However, we did not observe any alterations in SERCA2a expression levels by either acute or chronic overexpression of Hsp20. Collectively, these findings underscore the need for further studies on the interactions between chaperones and SR Ca regulatory proteins.
In heart failure, reduced output evokes an increase in catecholamines and other neuroendocrine factors, which negatively impact function by downregulation of ␤-adrenergic receptors and decreased protein kinase A activity, resulting in dephosphorylation of key phosphoproteins. 12 Overexpression of Hsp20 may have benefits in improving ventricular performance of failing hearts through targeting the PP1-PLN signaling axis. This is especially important in light of the elevated PP1 enzyme activity in SR. 19 However, it should be pointed out that disturbed Ca handling is not the only cause of heart failure. Loss of cardiomyocytes in the infarcted heart, increased load work on the surviving myocardium by the scar tissue, limited perfusion distal to coronary stenosis, suboptimal preload attributable to stiffness of the hypertrophic ventricle, and matrix remodeling are but a few additional factors that can contribute to global cardiac dysfunction. 37 Interestingly, Hsp20 also possesses cardioprotective effects by preserving the viability of injured myocardium. 2, 5, 6, 8, 9, 38 Thus, our findings lead to the suggestion that Hsp20 may have a double benefit in the failing myocardium by a combination of contractile-dependent and cardioprotectiondependent effects.
Taken together, this is the first study to our knowledge that defines a role for Hsp20 in enhancing cardiac contractility and Ca handling. In addition to its recognized cardioprotective effects against myocardial injuries, our results strongly support the hypothesis that Hsp20 may represent a "refined" target, augmenting contractility and providing cardiac protection in heart failure. 
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